Advertisement
Mr. Scott Grisanti, President and CEO of the Company, commented, "I amexcited to have these two proven industry leaders join our team, and believethese additions will position us to drive value for our customers andaccelerate our growth trajectory in the coming quarters. John brings a wealthof proven sales and business development experience and a track record ofbuilding successful teams and scaling results to meet and exceed goals. He isthe ideal person to drive our revenue as we introduce a wide range ofinnovative solutions to the healthcare marketplace. I worked closely with Daveat eResearchTechnology and look forward to benefiting from his strongorganizational and customer service skills. His ability to successfullydeliver technology as a service to solve substantial customer problems in verydemanding environments makes him the ideal person to partner with John, therest of the Aduromed team, and our customers as we move forward to capturethis large market opportunity."
Advertisement
Mr. Accardi brings more than 23 years of sales experience in high techcompanies with expertise in building organizations and developing new programlaunches in "start-up" environments and implementing creative strategies toexpand on existing relationships. Mr. Accardi joins Aduromed fromOracle/Siebel Systems, where was responsible for a $40 million line ofbusiness and led sales efforts for the financial services and insurancemarkets in the southeast and, earlier, served as senior director of Siebel'sNorth American Reseller Network. Previously, Mr. Accardi served as vicepresident of worldwide sales for Rasterex Software International, Inc., a $40million global software and services provider of valuable add-on products inthe Auto-cad market place. He joined Rasterex from Gary Brown & Associates, anAtlanta-based premier systems integrator in the mid-Atlantic geographic area.Mr. Accardi was vice president of sales and marketing, successfullypositioning the company as a clear industry leader and leveraging revenuegrowth by building strategic/OEM alliances with software leaders includingOracle Corporation, Microsoft, IBM, and others. Previously, he served as vicepresident and general manager for Computron Software, Inc., a $60 millionprovider of financial, workflow and COLD technology to the servicesindustries. In this role, he grew his region over 500% in one year while thecompany was losing $33 million worldwide. Prior, he served as vice presidentof sales, Distribution Division for Ross Systems, Inc., where he builtdivision sales from $2 million to $15 million in three years. Previously, heworked for Wang Laboratories, Inc., starting as a college sales trainee andprogressing to sales management responsibilities that included accountexecutive, branch and regional management positions.
Mr. Accardi commented, "The market for providing effective solutions foron-site treatment of regulated medical waste is large, underserved andgrowing, and Aduromed has the potential to emerge as a recognized leader inthis industry with a comprehensive range of technologies strategicallydesigned to address the unique needs of healthcare facilities of any size. Itis exciting to join Aduromed as we are launching this rebranding initiativeand rolling out innovative solutions. I look forward to developing a salesorganization that will drive sustainable revenue growth."
Mr. Laky joins Aduromed from eResearchTechnology, Inc. (Nasdaq: ERES)where he served for nine years and, most recently, was senior vice presidentand general manager of the eClinical Group. During his tenure, the eClinicalGroup achieved 98% on-time and on-budget delivery of complex "technology as aservice" solutions for the new drug development industry. In 2007 alone, Mr.Laky's team supported some 300 clinical trials at more than 1,000 researchsites around the world. Prior, he was director of western region professionalservices for Computron Software, Inc. and has worked as a senior auditor andtax accountant. At Aduromed, Mr. Laky will be responsible for professionalservices, including design services, installation services, and training, aswell as preventive and corrective maintenance programs, customer support andinformation technology.
"I am excited at the opportunity to work with the Aduromed team to deliverdesired outcomes for healthcare institutions seeking safe and economicalsolutions for on-site treatment of regulated medical waste," said Mr. Laky."There is an unmet need for an organization with comprehensive capabilities toemerge in this market, and the combination of Aduromed's technology and teamposition the company to build on its technology and thought leadership."
About Aduromed Industries, Inc.
Aduromed Industries, Inc. is a provider of innovative technology andservices for the onsite treatment and disposal of regulated medical waste.Aduromed's flagship MedClean(R) Series systems are fully integrated, turnkeytechnology solutions that enable hospitals and other healthcare providers tosafely, efficiently and cost-effectively convert bio-hazardous regulatedmedical waste into sterile, unrecognizable material suitable for disposal asmunicipal solid waste. Aduromed was founded in 1997 with corporateheadquarters, research and development and distribution facilities located inBethel, Connecticut. Further information on Aduromed can be found athttp://www.aduromed.com and in filings with the Securities and ExchangeCommission found at http://www.sec.gov.
Statements about our future expectations are "forward-looking statements"within the meaning of applicable Federal Securities Laws, and are notguarantees of future performance. When used herein, the words "may," "will,""should," "anticipate," "believe," "appear," "intend," "plan," "expect,""estimate," "approximate," and similar expressions are intended to identifysuch forward-looking statements. These statements involve risks anduncertainties inherent in our business, including those set forth in our mostrecent Annual Report on Form 10-K for the year ended December 31, 2007, filedwith the SEC on March 31, 2008, and other filings with the SEC, and aresubject to change at any time. Our actual results could differ materially fromthese forward-looking statements. We undertake no obligation to updatepublicly any forward-looking statement.
SOURCE Aduromed Industries, Inc.
